- Headquarters
- San Diego
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- recludixpharma.com
- Total Funding
- $81.5M
- Last Round
- $21.5M Series BJan 2026
About
Recludix Pharma is a clinical-stage biopharmaceutical company developing platform-based approaches to discover potent and selective inhibitors of challenging protein targets, with a focus on SH2 domain-containing proteins. The company's proprietary platform integrates structural biology, computational chemistry, and medicinal chemistry to tackle previously elusive but biologically validated targets. Recludix's lead programs target STAT6 and BTK for inflammatory diseases and oncology indications. The company was recognized as a Fierce 15 Biotech Company in 2024.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account